Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of ABBV-CLS-484 alone and in combination in advanced solid tumors
jRCT2031210036Phase 1Active, not recruiting
- Sponsor
- Calico Life Sciences
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of osunprotafib in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more (6 arms), sponsored by Calico Life Sciences. Primary endpoints: Maximum observed plasma/serum concentration (Cmax) of ABBV-CLS-484, Maximum observed plasma/serum concentration (Cmax) of PD-1 inhibitor and 16 more. Started May 2021; status: active, not recruiting.
02
Drugs
osunprotafib
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)microsatellite instability-high cancer
Beyond the preview
Go deeper on jRCT2031210036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210036.